Iodine uptake variability as a predictive biomarker for radioiodine therapy outcomes in Graves Disease: Validation through multi‐time‐point RAIU assessment in a 1249‐patient cohort
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16638 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yifan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Graves Disease, Iodine Radioisotopes, Iodine. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Scientific Research Fund of Anhui Medical University, the National Natural Science Foundation of China, Key Project of Natural Science Research of Anhui Higher Education Institution.
Abstract (Originalsprache)
Aims
To investigate the impact of iodine uptake variability (IUV) as a predictive biomarker associated with Graves Disease (GD) on the success rate of radioiodine (RAI) therapy for GD within 36 months, and discover IUV indicators for predicting GD prognosis. Materials and Methods This retrospective study included patients with GD who underwent RAI therapy at the Second Affiliated Hospital of Anhui Medical University between October 2012 and October 2022. Spearman correlation and maximal information coefficient analyses were used, along with hierarchical clustering and Kaplan–Meier survival analysis. Logistic and Cox regression were performed, and receiver operating characteristic curves and random sampling were used for validation.
Results
The study comprised 1249 patients (333 males (26.66%) and 916 females (73.34%)). After a 3‐year follow‐up, there were 1014 (81.18%) and 235 (18.82%) cases in the success and failure groups, respectively. IUV was an independent factor for GD prognosis under RAI treatment. RAIU‐Range/Max was recommended as a representative indicator for IUV, with a clinical threshold of 28.8%.
Conclusions
In this study, we proposed and defined IUV as a predictive biomarker for GD, and verified its impact on the prognosis of GD treated with RAI. Low IUV was associated with a poor clinical prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
- Graduate School, Anhui Medical University, Hefei, China.
- Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Anhui Public Health Clinical Center, Hefei, China.
- Intensive Care Unit, The first Affiliated Hospital of Anhui Medical University, Hefei, China.
ORCID-Profile: Yifan Li, Wenbin Wang, Tianrong Pan
Förderung
- Scientific Research Fund of Anhui Medical University
- the National Natural Science Foundation of China
- Key Project of Natural Science Research of Anhui Higher Education Institution
- Health Research Program of Anhui
- Anhui Province Clinical Medicine Transformation Special Project
Zitieren
APA
Li, Y., He, M., Hu, Z., Tian, H., Liu, Q., Yu, S., Li, R., Liu, N., Pan, L., Wang, W., & Pan, T. (2025). Iodine uptake variability as a predictive biomarker for radioiodine therapy outcomes in Graves Disease: Validation through multi‐time‐point RAIU assessment in a 1249‐patient cohort. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16638
Vancouver
Li Y, He M, Hu Z, Tian H, Liu Q, Yu S, et al. Iodine uptake variability as a predictive biomarker for radioiodine therapy outcomes in Graves Disease: Validation through multi‐time‐point RAIU assessment in a 1249‐patient cohort. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16638
BibTeX
@article{Li2025,
author = {Li, Yifan and He, Meiwen and Hu, Zilong and Tian, Hongjun and Liu, Qiming and Yu, Sijie and Li, Renming and Liu, Nina and Pan, Limeng and Wang, Wenbin and Pan, Tianrong},
title = {Iodine uptake variability as a predictive biomarker for radioiodine therapy outcomes in Graves Disease: Validation through multi‐time‐point RAIU assessment in a 1249‐patient cohort},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16638}
}
EUVIMED